Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
Clinical trial NCT03290079 · COMPLETED
Trial details
- NCT number
- NCT03290079
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-15
- Primary completion
- 2023-01-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.